Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) was the recipient of unusually large options trading on Monday. Stock investors purchased 7,953 put options on the stock. This is an increase of approximately 726% compared to the typical volume of 963 put options.

Shares of Zynerba Pharmaceuticals (ZYNE) opened at 7.60 on Thursday. Zynerba Pharmaceuticals has a 1-year low of $6.20 and a 1-year high of $25.95. The company’s market cap is $100.75 million. The stock has a 50 day moving average price of $17.54 and a 200-day moving average price of $19.50.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last announced its quarterly earnings results on Tuesday, August 1st. The company reported ($0.64) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.60) by $0.04. Equities research analysts forecast that Zynerba Pharmaceuticals will post ($2.46) earnings per share for the current year.

In other news, Chairman Armando Anido purchased 5,000 shares of the company’s stock in a transaction on Monday, May 15th. The stock was purchased at an average price of $19.70 per share, with a total value of $98,500.00. Following the completion of the purchase, the chairman now directly owns 336,012 shares in the company, valued at approximately $6,619,436.40. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO James E. Fickenscher purchased 5,200 shares of the company’s stock in a transaction on Friday, May 12th. The shares were purchased at an average cost of $19.82 per share, with a total value of $103,064.00. Following the purchase, the chief financial officer now owns 12,200 shares of the company’s stock, valued at $241,804. The disclosure for this purchase can be found here. Insiders own 10.02% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in ZYNE. JPMorgan Chase & Co. increased its position in shares of Zynerba Pharmaceuticals by 65,190.0% in the second quarter. JPMorgan Chase & Co. now owns 326,450 shares of the company’s stock worth $5,539,000 after buying an additional 325,950 shares during the last quarter. Chartwell Investment Partners LLC increased its stake in shares of Zynerba Pharmaceuticals by 19.9% in the second quarter. Chartwell Investment Partners LLC now owns 90,378 shares of the company’s stock valued at $1,534,000 after buying an additional 14,978 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Zynerba Pharmaceuticals by 192.1% in the second quarter. Bank of New York Mellon Corp now owns 35,529 shares of the company’s stock valued at $602,000 after buying an additional 23,364 shares during the last quarter. Rhumbline Advisers purchased a new stake in shares of Zynerba Pharmaceuticals during the second quarter valued at about $232,000. Finally, Schwab Charles Investment Management Inc. purchased a new stake in shares of Zynerba Pharmaceuticals during the second quarter valued at about $326,000. 31.08% of the stock is owned by hedge funds and other institutional investors.

ZYNE has been the subject of several research analyst reports. Zacks Investment Research lowered Zynerba Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. Jefferies Group LLC reaffirmed a “buy” rating and set a $32.00 price target on shares of Zynerba Pharmaceuticals in a research note on Thursday, May 25th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $28.00 price target on shares of Zynerba Pharmaceuticals in a research note on Tuesday. BidaskClub raised Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, July 12th. Finally, Oppenheimer Holdings, Inc. set a $8.00 price target on Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $17.89.

TRADEMARK VIOLATION NOTICE: This report was posted by Watch List News and is owned by of Watch List News. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://www.watchlistnews.com/zynerba-pharmaceuticals-sees-unusually-large-options-volume-zyne/1467322.html.

About Zynerba Pharmaceuticals

Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.

Receive News & Ratings for Zynerba Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.